Modification of the Method for the Determination of Zinc Content in Insulins by Atomic Absorption Spectrometry

Abstract

Scientific relevance. Zinc quantification in insulin active substances and preparations by atomic absorption spectrometry requires a sample preparation procedure using hydrochloric acid, a narcotic and psychotropic precursor. The exclusion of precursors from laboratory practice significantly reduces labour costs during analysis.Aim. This study aimed to modify the pharmacopoeial method for quantifying zinc in insulins with a view to eliminating drug precursors and to evaluate the applicability of the modified method across different insulin preparations.Materials and methods. The study considered insulin active substances and preparations of various types, dosage forms, and strengths. Zinc content determination involved using an Agilent 240FS atomic absorption spectrometer at a characteristic wavelength of 213.86 nm.Results. The authors selected the conditions for elemental analysis (nitric acid concentration, monochromator slit width, and flame stabilisation time) corresponding to the pharmacopoeial requirements for quantifying zinc in insulins (RSD ≤1.4%, standard zinc solution with a concentration of 0.8 mg/dm3, and calibration curve correlation coefficient ≥0.99). The study compared zinc content measurements in the studied insulin samples with hydrochloric acid or nitric acid as a solvent; it did not reveal any significant differences between the results obtained by the pharmacopoeial method and the modified method.Conclusions. The modified method enables analysts to quantify zinc in insulin preparations in various dosage forms without drug precursors.